Zactima - Tyrosine Kinase Inhibitor for Treatment of Lung Cancer
Key Data:
Drug (Brand / Generic)
Zactima (ZD6474)
Company / Licensee
AstraZeneca
Therapy Class
TKI
Product Description
Dual-acting TKI that targets VEGF receptor-2 (KDR) and EGFR
Current Indication
NSCLC
Market Sector
Oncology
Development Status
Phase III, Phase III; NDA and MAA submitted in July 2009 for 100mg of vandetanib in combination with chemotherapy
